Article
Cardiac & Cardiovascular Systems
Hidenori Tani, Taketaro Sadahiro, Yu Yamada, Mari Isomi, Hiroyuki Yamakawa, Ryo Fujita, Yuto Abe, Tatsuya Akiyama, Koji Nakano, Yuta Kuze, Masahide Seki, Yutaka Suzuki, Manabu Fujisawa, Mamiko Sakata-Yanagimoto, Shigeru Chiba, Keiichi Fukuda, Masaki Ieda
Summary: By conducting experiments on mice, this study found that cardiac reprogramming can repair chronic myocardial infarction, promote myocardial regeneration, and reduce fibrosis. The results of this study provide new insights for the treatment of chronic myocardial infarction and heart failure.
Article
Cardiac & Cardiovascular Systems
Hidenori Tani, Taketaro Sadahiro, Yu Yamada, Mari Isomi, Hiroyuki Yamakawa, Ryo Fujita, Yuto Abe, Tatsuya Akiyama, Koji Nakano, Yuta Kuze, Masahide Seki, Yutaka Suzuki, Manabu Fujisawa, Mamiko Sakata-Yanagimoto, Shigeru Chiba, Keiichi Fukuda, Masaki Ieda
Summary: Adult cardiomyocytes have limited regenerative ability, and the synthesis of extracellular matrix by cardiac fibroblasts (CFs) results in fibrosis and heart dysfunction after myocardial infarction (MI). The overexpression of cardiac transcription factors, MGTH, can directly reprogram CFs into induced cardiomyocytes (iCMs) and improve cardiac function in acute MI. However, it is unclear whether in vivo cardiac reprogramming can repair chronic MI with established scars.
Review
Medicine, General & Internal
Procolo Marchese, Francesca Gennaro, Giovanni Mazzotta, Claudia Acciarri, Stenio Amabili, Carlo Bonanni, Antonella D'Antonio, Domenico Delfino, Luca Di Vito, Manrico Partemi, Riccardo Pascucci, Andrea Romandini, Giancarla Scalone, Simona Silenzi, Pierfrancesco Grossi
Summary: Cardiac amyloidosis can lead to severe heart failure. Cardiac contractility modulation has been shown to be effective in treating symptomatic heart failure, but its application in patients with cardiac amyloidosis has not been studied. We present a case where cardiac contractility modulation therapy was effective in improving clinical status and reducing hospital admissions in a patient with TTR amyloidosis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Cardiac & Cardiovascular Systems
Osman Moneer, Vinay K. Rathi, James L. Johnston, Joseph S. Ross, Sanket S. Dhruva
Summary: The US FDA and CMS have different authorities in evaluating medical devices. While the FDA focuses on safety and effectiveness for market authorization, the CMS determines coverage for the beneficiaries. The CMS has enacted policies to automatically provide reimbursement for new devices authorized under the FDA's BDP, but this may lead to increased costs and uncertain benefits. To ensure better evidence generation, the FDA could be more selective in BDP eligibility and the CMS could independently review clinical evidence and make reimbursement contingent on clinical outcome benefit.
Article
Pharmacology & Pharmacy
Deborah M. Eaton, Thomas G. Martin, Michael Kasa, Natasa Djalinac, Senka Ljubojevic-Holzer, Dirk Von Lewinski, Maria Poettler, Theerachat Kampaengsri, Andreas Krumphuber, Katharina Scharer, Heinrich Maechler, Andreas Zirlik, Timothy A. McKinsey, Jonathan A. Kirk, Steven R. Houser, Peter P. Rainer, Markus Wallner
Summary: This study evaluated the effects of the pan-HDAC inhibitor SAHA on cardiac function in a heart failure model and found that SAHA can improve cardiomyocyte and contractile protein function by increasing myofilament calcium sensitivity and reducing diastolic tension.
Article
Medicine, Research & Experimental
Jack Rubinstein, Nathan Robbins, Karen Evans, Gabrielle Foster, Kevin Mcconeghy, Toluwalope Onadeko, Julie Bunke, Melanie Parent, Xi Luo, Jacob Joseph, Wen-Chih Wu
Summary: The Re-Prosper-HF study aims to investigate the potential of probenecid in improving cardiac function in patients with HFrEF. The study will assess the effects of oral probenecid for 180 days on systolic function, functional status, and self-reported health status.
Article
Biochemistry & Molecular Biology
Guoxing Xu, Azra Fatima, Martin Breitbach, Alexey Kuzmenkin, Christopher J. Fuegemann, Dina Ivanyuk, Kee Pyo Kim, Tobias Cantz, Kurt Pfannkuche, Hans R. Schoeler, Bernd K. Fleischmann, Juergen Hescheler, Tomo Saric
Summary: In this study, tetraploid pluripotent stem cells (PSCs) were successfully generated by fusion of mouse embryonic stem cells and somatic cells. The electrophysiological properties of the tetraploid fusion-derived PSCs and diploid ESC-derived cardiomyocytes (CMs) were compared. The results showed that the structural and electrophysiological properties of the two types of CMs were similar.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Cardiac & Cardiovascular Systems
Giulia Campostrini, Laura M. Windt, Berend J. van Meer, Milena Bellin, Christine L. Mummery
Summary: Human pluripotent stem cells have the potential to differentiate into all cells of the body, but applications in cardiac research have been slower due to the complex 3-dimensional cues required for cardiomyocyte function. Recent tissue engineering approaches have addressed issues such as cardiomyocyte immaturity, leading to new possibilities in disease modeling, drug discovery, and heart repair through three-dimensional bioengineered heart tissues.
CIRCULATION RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Yuta Okamura, Ryo Niijima, Satoshi Kameshima, Tomoko Kodama, Kosuke Otani, Muneyoshi Okada, Hideyuki Yamawaki
Summary: Hypertension is a major risk factor for cardiovascular diseases, caused by various abnormalities including blood vessel contractibility. This study investigated the effects of human omentin-1 on hypertensive complications in aged SHR. It was found that omentin-1 tended to improve left ventricular and renal failure in SHR, indicating its potential therapeutic role in hypertensive complications.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Pharmacology & Pharmacy
Matthew A. Wells, Louise E. See Hoe, Peter Molenaar, Sanne Pedersen, Nchafatso G. Obonyo, Charles McDonald, Weilan Mo, Mahe Bouquet, Kieran Hyslop, Margaret R. Passmore, Nicole Bartnikowski, Jacky Y. Suen, Jason N. Peart, David C. McGiffin, John F. Fraser
Summary: The study found that brain stem death and transplantation may impair the contractility of the donor heart, especially the right ventricle. For the donor heart, this contractile dysfunction appears to be independent of changes to beta(1)-adrenoceptor sensitivity.
PHARMACOLOGICAL RESEARCH
(2021)
Article
Cardiac & Cardiovascular Systems
Xi Lou, Yawen Tang, Lei Ye, Danielle Pretorius, Vladimir G. Fast, Asher M. Kahn-Krell, Jue Zhang, Jianhua Zhang, Aijun Qiao, Gangjian Qin, Timothy Kamp, James A. Thomson, Jianyi Zhang
Summary: The study demonstrates that human cardiac muscle patches containing three types of cardiac cells derived from human pluripotent stem cells significantly improved cardiac function, reduced infarct size, and promoted cardiac maturation in a pig model of myocardial infarction. The inclusion of cardiac fibroblasts in the cardiac patches enhanced the maturity and function of cardiac muscle cells. Transplantation of cardiac patches with cardiac fibroblasts resulted in better cardiac recovery and engraftment compared to patches without fibroblasts.
CARDIOVASCULAR RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Gregory J. Bittle, David Morales, Nicholas Pietris, Nathaniel Parchment, Dawn Parsell, Kiel Peck, Kristopher B. Deatrick, Luis Rodriguez-Borlado, Rachel R. Smith, Linda Marban, Sunjay Kaushal
Summary: In a juvenile porcine model, human CDC-derived exosome administration showed significant preservation of RV systolic function in the setting of acute pressure overload, leading to improved cardiac function and reduced cardiomyocyte hypertrophy. These acellular preparations may be superior to whole cells and represent a novel therapeutic approach to clinical myocardial injury.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2021)
Article
Cell Biology
Tung-Sheng Chen, Shou-Ying Chuang, Chia-Yao Shen, Tsung-Jung Ho, Ruey-Lin Chang, Yu-Lan Yeh, Chia-Hua Kuo, B. Mahalakshmi, Wei-Wen Kuo, Chih-Yang Huang
Summary: High-glucose suppresses mesenchymal stem cell functions in diabetes mellitus. Resveratrol enhances MSC functions and improves survival markers, AMPK/Sirt1 axis, and apoptotic markers. Pretreatment with resveratrol may have clinical potential in treating heart failure in diabetic patients.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Medicine, Research & Experimental
Toshihide Kashihara, Risa Mukai, Shin-ichi Oka, Peiyong Zhai, Yasuki Nakada, Zhi Yang, Wataru Mizushima, Tsutomu Nakahara, Junco S. Warren, Maha Abdellatif, Junichi Sadoshima
Summary: The heart utilizes multiple adaptive mechanisms to maintain pump function, with YAP playing a crucial role in inducing compensatory cardiac hypertrophy through promoting glycolysis and upregulating the GLUT1 gene. This leads to the accumulation of glycolytic metabolites and ultimately promotes cardiac hypertrophy.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Cardiac & Cardiovascular Systems
Pieter Martens, Matthias Dupont, Jeroen Dauw, Petra Nijst, Lieven Herbots, Paul Dendale, Pieter Vandervoort, Liesbeth Bruckers, Wai Hong Wilson Tang, Wilfried Mullens
Summary: The study demonstrated that treatment with ferric carboxymaltose (FCM) in patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency led to significant improvements in cardiac function, including LVEF, LVESV, and cardiac force-frequency relationship.
EUROPEAN HEART JOURNAL
(2021)